Crimean‐Congo hemorrhagic fever (CCHF) is a thick‐borne viral zoonotic disease.
The pathogenesis and the reasons why cases have a mild or severe course in CCHF
have not yet been explained. In this study, we investigated the relationship between
promoter ‐2518 A/G single‐nucleotide polymorphism (SNP) of the MCP‐1 gene and
the clinical course of CCHF. The MCP‐1‐2518 A/G SNP (rs1024611) frequency
was examined in 128 virologically/serologically confirmed CCHF patients and
181 healthy controls by using the PCR‐RFLP method. When CCHF patients
and controls were compared, no significant difference was found between genotype
distributions and allele frequencies of the ‐2518 A/G SNP of MCP‐1 gene (P > .05).
Compared to the AA genotype, both AG (P = .016; OR = 2.57) and GG genotype
(P = .039; OR = 3.43) were found with significantly higher frequencies in mild/moderate
cases than in severe cases. Compared to the AG + GG genotype, AA showed a
significant risk for severe CCHF (60.0% vs 38.4%, P = .02; OR = 2.41). In contrast, the
AG genotype showed a significant protective effect against severe disease compared
to AA + GG genotype (29.1% vs 47.9%, P = .013; OR = 2.58). Compared to mild/
moderate cases, the A allele was found to be significantly higher in severe cases
(0.745 vs 0.623, P = .039; OR = 1.77). However, no significant relationship was found
between fatal and nonfatal cases in terms of genotype or allele frequencies (P > .05).
In conclusion, both ‐2518 AA genotype and A allele of MCP‐1 were associated
with disease severity, and the AG genotype had a protective effect against a severe
disease course in CCHF patients.